Read by QxMD icon Read

Stem cell trasplant

Juan-Manuel Sancho, Rafael Duarte, Laura Medina, Sergi Querol, Pedro Marín, Anna Sureda
BACKGROUND AND OBJECTIVE: Poor mobilization of peripheral blood stem cells (CD34(+) cells) from bone marrow is a frequent reason for not reaching the autologous stem cell trasplantation (SCT) procedure in patients diagnosed with lymphoma or myeloma. Plerixafor, a reversible inhibitor of the binding of stromal cell-derived factor 1 to its cognate receptor CXCR4, has demonstrated a higher capacity for the mobilization of peripheral blood stem cells in combination with granulocyte colony stimulating factor (G-CSF) compared with G-CSF alone...
September 2, 2016: Medicina Clínica
Lidiane Miotto Barretta, Lúcia Marinilza Beccaria, Cláudia Bernardi Cesarino, Maria Helena Pinto
OBJECTIVE: to identify the model, average length of stay on site and complications of central venous catheter in patients undergoing transplant of hematopoietic stem cells and verify the corresponding relationship between the variables: age, gender, medical diagnosis, type of transplant, implanted catheter and insertion site. METHOD: a retrospective and quantitative study with a sample of 188 patients transplanted records between 2007 and 2011. RESULTS: the majority of patients used Hickman catheter with an average length of stay on site of 47...
June 7, 2016: Revista Latino-americana de Enfermagem
R Martino, G Bautista, R Parody, I García, A Esquirol, M Rovira, J R Cabrera, C Regidor, R Fores, J A García-Marco, D Serrano, P Barba, I Heras, F J Marquez-Malaver, I Sánchez-Ortega, R Duarte, S Saavedra, J Sierra, L Vazquez
BACKGROUND: Umbilical cord blood transplantation (CBT) is an established alternative source of stem cells in the setting of unrelated transplantation. When compared with other sources, single-unit CBT (sCBT) is associated with a delayed hematologic recovery, which may lead to a higher infection-related mortality (IRM). Co-infusion with the sCBT of CD34+ peripheral blood stem cells from a third-party donor (TPD) (sCBT + TPDCD34+) has been shown to markedly accelerate leukocyte recovery, potentially reducing the IRM...
April 2015: Transplant Infectious Disease: An Official Journal of the Transplantation Society
Alexios Matikas, George Kanellis, Christos Papadimitriou, Theodora Papadaki, Athanasios Kotsakis, Meletios A Dimopoulos, Vassilis Georgoulias
BACKGROUND: Plasmablastic lymphoma (PBL) is a rare entity which is often causally related to infection by the Human Immunodeficiency Virus (HIV). Despite its predilection for oral cavity involvement, multiple cases of extra-oral involvement have been reported in the literature, more often among immunocompetent individuals. CASE REPORT: Herein we present the first case of primary PBL of the breast in an otherwise immunocompetent 36-year-old woman who was successfully treated with consolidation megatherapy and autologous stem cell transplantation...
September 2014: Anticancer Research
Javier Briones, Silvana Novelli, José A García-Marco, José F Tomás, Teresa Bernal, Carlos Grande, Miguel A Canales, Antonio Torres, José M Moraleda, Carlos Panizo, Isidro Jarque, Francisca Palmero, Miguel Hernández, Eva González-Barca, Dulce López, Dolores Caballero
No abstract text is available yet for this article.
July 2014: Haematologica
Christelle Ferrà, Jaime Sanz, Miguel-Angel Díaz-Pérez, Mireia Morgades, Jorge Gayoso, José-Rafael Cabrera, Teresa Villaescusa, María-Antonia Sampol, Francesc Fernández-Avilés, Carlos Solano, Miguel Ortín, Rafael Duarte, Marian Cuesta, Inmaculada Heras, Javier de la Serna, José-María Moraleda, Cristina Barrenetxea, Marta González-Vicent, Guillermo Sanz, Josep-Maria Ribera
Strategies for reversing graft failure (GF) after allogeneic stem cell transplant (SCT) depend on the options available in each situation. GF was reported in 16 Spanish institutions from January 2006 to July 2011. Primary GF was defined as an absolute neutrophil count (ANC) > 0.5 × 10(9)/L not reached by day + 28 after SCT from peripheral blood (PB) or bone marrow (BM) progenitors and by day + 42 after SCT from unrelated cord blood (UCB) progenitors. Secondary GF was defined as a recurrent ANC < 0.5 × 10(9)/L...
March 2015: Leukemia & Lymphoma
R Hladun, I Badell, M González, A M Martínez, J Sánchez de Toledo, M T Olivé, M E González, I Elorza, C Díaz de Heredia
INTRODUCTION: Children with primary immunodeficiency have severe life-threatening infections and a higher prevalence of autoimmune problems, allergy and lymphoproliferative disorders. Allogenic hematopoietic stem cell transplantation has been the only potentially curative option. PATIENTS AND METHODS: Patients with primary immunodeficiency underwent allogenic stem cell transplantation in the period 1985-2011, and registered in the Spanish Working Party for Bone Marrow Transplantation in Children...
February 2015: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría (A.E.P.)
R Bracaglia, M D'Ettorre, S Gentileschi, G Mingrone, D Tambasco
BACKGROUND: Lipomas are the most common type of soft tissue benign tumor. They can be either isolated entities or involved in a multiple lipomatosis, which may have a familial basis or be an acquired condition. AIM: Chemotherapy and/or blood stem cell transplantation may be plausible causes of multiple lipomatosis. MATERIALS AND METHODS: A 28 year-old patient was diagnosed with non-seminomatous germ cell left testicular cancer. The patient was addressed to chemotherapy and peripheral blood stem cell chemomobilization...
2014: European Review for Medical and Pharmacological Sciences
Jaime Sanz, Alessandra Picardi, Juan C Hernández Boluda, Carmen Martín, Christelle Ferrá, Chiara Nozzoli, Marta Gonzalez-Vicent, Alessandro Rambaldi, David Valcarcel, Amparo Verdeguer, David Serrano, Cristina Díaz de Heredia, María Jesús Pascual, Raquel de Paz, Pau Montesinos, Benedetta Bartolozzi, Alessandra Algarotti, Miguel A Sanz, William Arcese, Guillermo F Sanz
Myeloablative single-unit umbilical cord blood transplantation (sUCBT) using busulfan, thiotepa, fludarabine, and antithymocyte globulin (Grupo Español de Trasplante Hematopoyético [GETH]-2005 protocol) resulted in high rates of engraftment and high antitumor activity. We designed a new graft-versus-host disease prophylaxis, substituting long-term steroids with mycophenolate mofetil together with a slight reduction of antithymocyte globulin (GETH/Gruppo Italiano Trapianto Midollo Osseo [GITMO]-2008 protocol)...
September 2013: Biology of Blood and Marrow Transplantation
J Sanz, J C H Boluda, C Martín, M González, C Ferrá, D Serrano, C D de Heredia, C Barrenetxea, A M Martinez, C Solano, M A Sanz, G F Sanz
Attempts to optimize outcomes in cord blood transplantation (CBT) by using new conditioning regimens and standardization of cord blood unit selection are warranted. In all, 88 patients (18 children and 70 adults) with hematological malignancy from nine Spanish institutions underwent a single-unit CBT after an i.v. BU-based myeloablative conditioning regimen. All evaluable patients except one engrafted. The overall cumulative incidence (CI) of myeloid engraftment was 94% at a median time of 19 days. In multivariate analysis, nonadvanced disease stage was the only factor with a favorable impact on myeloid engraftment...
October 2012: Bone Marrow Transplantation
Anna Sureda, Carme Canals, Reyes Arranz, Dolores Caballero, Josep Maria Ribera, Mats Brune, Jacob Passweg, Rodrigo Martino, David Valcárcel, Joan Besalduch, Rafael Duarte, Angel León, Maria Jesus Pascual, Ana García-Noblejas, Lucia López Corral, Bianca Xicoy, Jordi Sierra, Norbert Schmitz
BACKGROUND: Although Hodgkin's lymphoma is a highly curable disease with modern chemotherapy protocols, some patients are primary refractory or relapse after first-line chemotherapy or even after high-dose therapy and autologous stem cell transplantation. We investigated the potential role of allogeneic stem cell transplantation in this setting. DESIGN AND METHODS: In this phase II study 92 patients with relapsed Hodgkin's lymphoma and an HLA-identical sibling, a matched unrelated donor or a one antigen mismatched, unrelated donor were treated with salvage chemotherapy followed by reduced intensity allogeneic transplantation...
February 2012: Haematologica
Christelle Ferrà, María-José Jiménez-Lorenzo, Evarist Feliu, Josep-Maria Ribera et al.
No abstract text is available yet for this article.
June 25, 2011: Medicina Clínica
J M Calvo-Villas, A Martín, E Conde, A Pascual, I Heras, R Varela, J de la Rubia, M J Ramirez, J L Díez-Martín, C Panizo, M J Rodríguez-Salazar, M J Pascual, E M Donato, E González-Barca, M D Caballero
BACKGROUND: We have investigated if rituximab-based salvage regimens improve response rates and survival of patients with diffuse large B-cell lymphoma (DLBCL) relapsing after an autologous stem-cell transplantation (ASCT). PATIENTS AND METHODS: We have retrospectively analyzed 82 patients with DLBCL who received salvage therapy for relapse or progression after ASCT. Patients were divided into two groups, according to whether rituximab-based salvage regimens were given (n = 42, 'R-' group) or not (n = 40, 'R+' group) after ASCT...
September 2010: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Christelle Ferrá, Jaime Sanz, Rafael de la Cámara, Guillermo Sanz, Arancha Bermúdez, David Valcárcel, Montserrat Rovira, David Serrano, Dolores Caballero, Ildefonso Espigado, Mireia Morgades, Inmaculada Heras, Carlos Solano, Rafael Duarte, Cristina Barrenetxea, Ana García-Noblejas, José L Díez-Martin, Arturo Iriondo, Enric Carreras, Jordi Sierra, Miguel-Angel Sanz, Josep-Maria Ribera et al.
Adults with high-risk acute lymphoblastic leukemia (HR-ALL) have a poor outcome with standard chemotherapy and usually undergo unrelated stem cell transplantation (SCT) if a matched sibling donor is not available. We analyzed the outcome of adult patients with unrelated SCT for HR-ALL and studied the possible effect of the hematopoietic stem cell source of the transplant. A total of 149 adult patients (median age, 29 years, range, 15-59 years) with HR-ALL underwent unrelated SCT in 13 Spanish institutions between 2000 and 2007...
July 2010: Biology of Blood and Marrow Transplantation
Josep-Maria Ribera, Albert Oriol, Marcos González, Belén Vidriales, Salut Brunet, Jordi Esteve, Eloy Del Potro, Concepción Rivas, Maria-José Moreno, Mar Tormo, Victoria Martín-Reina, Josep Sarrá, Ricardo Parody, Jaime Pérez de Oteyza, Encarna Bureo, Maria-Teresa Bernal
BACKGROUND: Imatinib, given concurrently or alternating with chemotherapy, has improved the response and survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) but relapses are still frequent. The aim of this study was to evaluate the feasibility and results of giving imatinib concurrently with intensive chemotherapy, stem cell transplantation and post-transplant imatinib maintenance therapy in patients with newly diagnosed Ph(+) ALL. DESIGN AND METHODS: This was a phase II study of patients with newly diagnosed Ph(+) ALL given standard chemotherapy, together with imatinib (400 mg/day) until stem cell transplantation, followed by imatinib maintenance therapy for all patients regardless of the molecular status of the disease...
January 2010: Haematologica
E Roig, L Almenar, F González-Vílchez, G Rábago, J Delgado, M Gómez-Bueno, M G Crespo-Leiro, J M Arizón, L de la Fuente, N Manito
Amyloidosis (Am), a systemic disease, has poor prognosis because of organ damage produced by protein deposition in the extracellular space. Although heart transplantation (HTx) is possible, donor availability concerns and high mortality make this approach controversial. The Spanish Registry for Heart Transplantation includes 25 Am patients (54 +/- 9 years): 13 with AL type, 2 with AA and 10 with TTR mutation. Fifteen patients (60%) died during follow-up (4.9 +/- 1.3 years): 9 AL-Am patients, both AA-Am patients and 4 with TTR-Am...
June 2009: American Journal of Transplantation
Carmen Martínez, Carlos Solano, Christelle Ferrá, Antonia Sampol, David Valcárcel, José Antonio Pérez-Simón
We conducted a phase II trial to investigate the safety and efficacy of alemtuzumab in treating steroid-refractory acute graft-versus-host disease (aGVHD) grade II or higher after stem cell transplantation. Ten adult patients (6 with aGVHD grade III and 4 with aGVHD grade IV) were included in the study. Nine patients had gastrointestinal tract involvement, 7 had skin involvement, and 5 had liver involvement. Five patients responded to treatment, 2 with complete response and 3 with partial response. Eight infectious events (4 of grade 3-4) and 7 cytomegalovirus (CMV) reactivations were observed...
May 2009: Biology of Blood and Marrow Transplantation
Alejandro Martín, Eulogio Conde, Montserrat Arnan, Miguel A Canales, Guillermo Deben, Juan M Sancho, Rafael Andreu, Antonio Salar, Pedro García-Sanchez, Lourdes Vázquez, Sara Nistal, María-José Requena, Eva M Donato, José A González, Angel León, Concepción Ruiz, Carlos Grande, Eva González-Barca, María-Dolores Caballero
BACKGROUND: The role of re-treatment with rituximab in aggressive B-cell lymphomas still needs to be defined. This study evaluated the influence of prior exposure to rituximab on response rates and survival in patients with diffuse large B-cell lymphoma treated with rituximab plus etoposide, cytarabine, cisplatinum and methylprednisolone (R-ESHAP). DESIGN AND METHODS: We retrospectively analyzed 163 patients with relapsed or refractory diffuse large B-cell lymphoma who received R-ESHAP as salvage therapy with a curative purpose...
December 2008: Haematologica
Jose A Pérez-Simón, Rodrigo Martino, Dolores Caballero, David Valcarcel, Noemi Rebollo, Rafael de la Cámara, Javier Pérez de Oteiza, Inmaculada Heras, Maria V Calvo, Jordi Sierra, Jesús F San Miguel
In the current study, we have analyzed the efficacy of cyclosporine A (CSA) plus mycophenolate mofetil (MMF) as graft-versus-host disease (GVHD) prophylaxis in the fludarabine plus melphalan or busulfan reduced intensity regimen (RIC) setting in a series of 44 patients receiving allogeneic transplantation from an unrelated donor. Only 23% were in the first complete remission at the time of transplant. Cumulative incidence of grades II-IV and III-IV acute GVHD (aGVHD) was 53% and 23%, respectively. Fifty-six percent had equal to or greater than grade 2 gut involvement...
June 2008: Biology of Blood and Marrow Transplantation
Reyes Arranz, Eulogio Conde, Carlos Grande, Maria Victoria Mateos, Marco Gandarillas, Carmen Albo, Juan J Lahuerta, José M Fernández-Rañada, Miguel T Hernández, Natalia Alonso, José A García Vela, Sebastián Garzón, José Rodríguez, Dolores Caballero et al.
OBJECTIVES: The role of high-dose therapy and autologous stem-cell transplantation (HDT/ASCT) in the up-front treatment of poor-risk aggressive lymphoma is still unknown. We conducted a prospective multi-centre trial with dose-escalated CHOP (MegaCHOP) and tailored intensification prior to HDT/ASCT according to early response assessed by CT and gallium scan (Ga67S). PATIENTS AND METHODS: Eighty-six patients with newly diagnosed and Ga-67 avid aggressive B-cell lymphoma received MegaCHOP for three courses and were evaluated for response by CT and Ga67S...
March 2008: European Journal of Haematology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"